Interleukin-23 inhibitors demonstrate high effectiveness in the treatment of a real-world cohort of 82 psoriatic patients regardless of the HLA-Cw6 status.
Carmen Alejandra Rubio-MunizAlba López-ValleManuel Agud-DiosJorge Arroyo-AndresRaquel Rivera-DíazPublished in: Dermatologic therapy (2022)